Navigation Links
China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group
Date:12/6/2011

160;

Allegation 2

CMED sold its primary business segment, responsible for the majority of the firm’s sales since inception, to the chairman at less than 2x trailing EBITDA.We believe that this suspicious looking transaction was designed to cover up that the Chinese FDA was about to (or already had) suspended CMED’s permit to sell HIFU products, thus rendering CMED’s core business segment worthless almost overnight. (Source: Glaucus Research Group)

Again, the allegation by Glaucus indicates its team’s lack of commercial knowledge. Mr. Wu would not pay US$53.5 million to buy the business from the Company if he knew that the HIFU business would be suspended by SFDA around mid-2009 before the purchase in December 2008. It was fine to let the suspension happen as the decision of SFDA, a government agency, was not within the control of the Company or its management.  Glaucus’s reasoning is also conflicting.  If the business is known to be worthless, nobody should buy the business even at 2X EBITDA of historical financial results.  The Company provided a detailed discussion for the sale of the HIFU business to Mr. Wu in the Company’s press release in December 2008 while Glaucus only extracted partial information favorable to Glaucus’s analysis and allegation.  Besides, the sale of the HIFU business to Mr. Wu was part of the internal investigation conducted in 2009.  The investigation did not find anything wrong for the sale of the business.  The investigators reviewed the independent business evaluation of the HIFU prepared by a Big Four firm.

Allegation 3

Despite a purportedly profitable business, CMED is a serial capital raiser and has not generated free cash flow for most of its history. The company has spent twice as much on “investing activities” as it has purportedly generated from operations, so much like a typi
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. China Health Resource Receives Letter of Intent for DAR Totaling About $8 Million
2. China Health Resource Completes Key Research Project - New Proprietary Product Lines
3. The Outlook for Medical Devices in Brazil, Russia, India & China
4. China Health Resource Goes Global
5. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012
6. China Nepstar Chain Drugstore Reports Third Quarter 2011 Financial Results
7. Sinovac to Present at 23rd Annual Piper Jaffray Health Care Conference and HK/China Mini Conference 2011 (Healthcare)
8. China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results
9. China Medical Technologies Reports Second Fiscal Quarter Financial Results
10. The Outlook for Pharmaceuticals in Brazil, Russia, India & China
11. RNL Opens the Worlds Largest Stem Cell Medical Center in Beijing, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Zimmer Holdings, Inc. (NYSE ... fixation system for trauma patients. Available in ... ® External Fixation System from Zimmer is a ... materials.   The XtraFix System allows surgeons ... the external fixation process, resulting in saved time, costs and ...
(Date:3/27/2015)... -- Report Details  New study ... What does the future hold for top ... brand new report shows you potential revenues to 2025, ... Our 242-page report provides 185 tables, charts, and graphs. ... the future market prospects. Our new study lets you ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused ... (TLR8) candidates for the treatment of cancer, respiratory ... randomized, placebo controlled clinical trial evaluating VTX-1463 for ... that VTX-1463 significantly improved allergy symptoms based on ...
... R.I., Oct. 7 CVS Caremark ... it has appointed Jonathan C. Roberts as Chief ...  Roberts, who is currently Executive Vice President, Rx ... assume the leadership of PBM operations, mail service ...
Cached Medicine Technology:VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2CVS Caremark Appoints Jonathan C. Roberts as PBM Chief Operating Officer 2
(Date:3/28/2015)... India Network visitor health insurance ... to all visitors who purchase the plan before arrival ... encouraged to purchase the insurance program as soon as ... coverage for pre-existing medical conditions. Parents and grandparents traveling ... conditions with serious consequences to their health. Many visitors ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 One in ... according to research presented today at the American Orthopaedic ... The study examined the long term success of surgery ... “We examined survey data from 242 patients who underwent ... Justin P. Roe, MBBS, FRACS, from North Sydney Orthopaedic ...
(Date:3/28/2015)... March 28, 2015 Genomic medicine experts ... mesothelioma, revealing, for the first time, key information for ... to read the newly posted story on the ... University of British Columbia, the British Columbia Cancer Agency, ... to reveal underlying molecular alterations and mutations that can ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... 2015 Purity Products®, a leading ... the release of their revolutionary new weight loss ... randomized, double-blind, placebo-controlled clinical studies to be effective ... size. MuffinStop™ is a combination of two traditionally ... fused together to create one of the most ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
... -- Preliminary results from the first-of-its-kind Clinical Evaluation ... today at the Society of Gastroenterology Nurses and Associates, ... The study indicated that while there are written ... participated in the study, significant variation in manual reprocessing ...
... Data on frequency of resistance development and safety ... Microbiology and Infectious Diseases (ECCMID)SAN DIEGO, May 18 ... best-in-class drugs for the treatment of serious bacterial ... of torezolid (TR-701), a novel antibiotic that is ...
... Alcon and Initial Payments from New Galderma Collaboration ... May 18 NovaBay Pharmaceuticals, Inc. (NYSE Amex: ... developing first-in-class anti-infective products for the treatment and ... causing resistance, reported today its financial results and ...
... Dad and Give Back To A Worthy CauseLOS ANGELES , ... figures in their lives and Teleflora, the world,s leading ... run with its Father,s Day product line-up. Adding extra batting ... Prostate Cancer Foundation (PCF), to help raise awareness for prostate cancer ...
... - New data to be presented on Abbott,s market-leading ... Abbott,s next-generation drug eluting stent in developmentBARCELONA, Spain, May ... announced the company,s schedule of major events and news ... 22. These include the presentation of new data from ...
Cached Medicine News:Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 2Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 3Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 4Health News:Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9Health News:Teleflora Hits it out of the Park With Flower Gifts for Father's Day 2Health News:Teleflora Hits it out of the Park With Flower Gifts for Father's Day 3Health News:Abbott Announces EuroPCR 2009 Activities 2Health News:Abbott Announces EuroPCR 2009 Activities 3Health News:Abbott Announces EuroPCR 2009 Activities 4
... Roche Diagnostics Task Targeted Automation ... state-of-the-art automation of pre- and ... decapping, sorting / archiving of ... bar code labeled secondary tubes. ...
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
... Save precious time and gain efficiency ... Lab Automation System (LAS), the high-throughput ... sample-processing capabilities. The Olympus OLA2500 LAS ... designed for medium- to high-volume laboratories. ...
The Freedom EVO series platform offers a choice of flexible, scalable solutions for current and future application needs....
Medicine Products: